The price of Edwards Lifesciences Corporation (NYSE:EW) shares last traded on Wall Street fell -1.13% to $76.09.
Based on available information, 30 analysts follow Edwards Lifesciences Corporation (NYSE:EW). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $110.00 and a low of $75.00, we find $99.00. Given the previous closing price of $76.96, this indicates a potential upside of 28.64 percent. EW stock price is now -9.50% away from the 50-day moving average and -6.85% away from the 200-day moving average. The market capitalization of the company currently stands at $46.31B.
Among analysts, 13 rate the stock a hold while 13 rate it a buy. Brokers who have rated the stock have averaged $97.09 as their price target over the next twelve months.
With the price target of $107, Robert W. Baird recently initiated with Outperform rating for Edwards Lifesciences Corporation (NYSE: EW).
In other news, Chopra Daveen, CVP, TMTT sold 8,500 shares of the company’s stock on Sep 06. The stock was sold for $646,609 at an average price of $76.07. Upon completion of the transaction, the CVP, TMTT now directly owns 23,950 shares in the company, valued at $1.82 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 05, Director MUSSALLEM MICHAEL A sold 29,350 shares of the business’s stock. A total of $2,226,491 was realized by selling the stock at an average price of $75.86. This leaves the insider owning 4,486 shares of the company worth $0.34 million. Insiders disposed of 869,859 shares of company stock worth roughly $66.19 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EW stock. A new stake in Edwards Lifesciences Corporation shares was purchased by STONEHAGE FLEMING FINANCIAL SERVICES HOLDINGS LTD during the first quarter worth $92,184,000. BOWEN HANES & CO INC invested $27,023,000 in shares of EW during the first quarter. In the first quarter, UNISUPER MANAGEMENT PTY LTD acquired a new stake in Edwards Lifesciences Corporation valued at approximately $15,236,000. ALPHINITY INVESTMENT MANAGEMENT PTY LTD acquired a new stake in EW for approximately $13,453,000. RETIREMENT SYSTEMS OF ALABAMA purchased a new stake in EW valued at around $10,484,000 in the second quarter. In total, there are 1,798 active investors with 84.90% ownership of the company’s stock.
A candlestick chart of Edwards Lifesciences Corporation (NYSE: EW) showed a price of $77.03 on Thursday morning. During the past 12 months, Edwards Lifesciences Corporation has had a low of $67.13 and a high of $98.35. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 3.20, and a quick ratio of 2.30. According to the stock market information, the enterprise value for the company is $45.96B, which is based on a 33.71 price-to-earnings ratio, a 3.49 price-to-earnings-growth ratio, and a beta of 1.03. The fifty day moving average price for EW is $83.80 and a two-hundred day moving average price translates $81.69 for the stock.
The latest earnings results from Edwards Lifesciences Corporation (NYSE: EW) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at $0.66, beating analysts’ expectations of $0.65 by 0.01. This compares to $0.65 EPS in the same period last year. The net profit margin was 24.60% and return on equity was 22.80% for EW. The company reported revenue of $1.53 billion for the quarter, compared to $1.37 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.38 percent. For the current quarter, analysts expect EW to generate $1.48B in revenue.
